| 초록 |
Pancreatic cancer is one of the most deadly of all types of cancer, with more than 200,000 deaths worldwide every year. Gemcitabine (2',2'-difluorodeoxycytidine, GEM), a chemotherapeutic agent, is a first-choice drug in the treatment of pancreatic cancer. However, very short plasma half-life of GEM limits its efficiency in clinical treatment. To overcome such limitation, a nano-biohybrids system has been proposed through intercalation of GEM into the interlayer of montmorillonite nanoparticles (MMT) by ion exchange method. Nano-biohybrids hydrogel (PEG-PCLA/MMT-GEM) were prepared by dispersion of MMT-GEM complex into the temperature- sensitive injectable PEG-PCLA hydrogel to controlled release of GEM. The system was characterized by X-ray diffraction (XRD), zeta potential and Fourier transformed infrared (FT-IR). The in vitro gemcitabine release showed that the nanohybrids hydrogel can be successfully serve as controlled release of GEM in the treatment of pancreatic cancer. |
